NuoHui Health Establishes International R&D Center at Hong Kong Science Park Led by Former Exact Sciences Executive
New Horizon Health (6606.HK) todayAnnouncing Dr. Shi Shuangmei(Dr. Shih) assumed the position of Vice President of Research and Development, taking full responsibility for the establishment and development of New Horizon Health’s International R&D Center.
New Horizon Health’s International R&D Center is established at the Hong Kong Science Park, aiming to attract top-tier global talent in biotechnology and high-tech industries. The center focuses on technological innovation and product development in multi-omics cancer screening, including next-generation sequencing (NGS) technologies, while simultaneously advancing overseas commercialization and globally synchronized clinical trials. The first phase of the R&D center covers 10,000 square feet, with an estimated total investment of approximately HK$100 million, and will initially recruit 20–30 scientists.
Dr. Shi specializes in the research, development, and practical application of molecular diagnostics and next-generation sequencing (NGS) technologies. Having served as a senior R&D executive at leading international biotechnology companies, he has repeatedly led global teams to successfully launch diagnostic and screening products for cancer and other major diseases. He brings over 16 years of extensive experience in product development and team management.
Prior to joining New Horizon Health, Dr. Shi served as the Director of Research and Development at Natera, a leading U.S. brand in non-invasive prenatal testing. She led her team in developing diagnostic technologies for organ transplant rejection and successfully launched the Prospera™ series of in vitro diagnostic products for liver, kidney, heart, and lung transplantation in the U.S. and European markets. From 2017 to 2021, she worked at Exact Sciences, a benchmark company in U.S. cancer screening, where she led cross-functional R&D teams to drive the development and commercialization of screening and diagnostic products for breast, colorectal, lung, and prostate cancers. Previously, Dr. Shi held positions as an R&D project lead or core R&D member at several U.S.-based unicorn startups specializing in next-generation sequencing (NGS) and molecular diagnostics. She holds multiple patents and has published numerous academic research papers in renowned international journals. Dr. Shi earned dual bachelor’s degrees in Biology and Food Science & Nutrition, as well as a master’s degree in Molecular Biology from The Chinese University of Hong Kong. She furthered her studies at the University of Maryland, where she obtained a Ph.D. in Molecular Nutrition.
“Dr. Shi boasts top-tier educational credentials from both Hong Kong and the United States, as well as extensive experience at leading international molecular diagnostics companies. His expertise will undoubtedly accelerate New Horizon Health’s progress in multi-omics R&D,” said Zhu Yeqing, Chairman and CEO of New Horizon Health. “This year, New Horizon has pursued a dual-track strategy in Hong Kong, achieving notable progress in both marketing and R&D capacity building. The establishment of New Horizon’s International R&D Center in Hong Kong, situated within the Guangdong-Hong Kong-Macao Greater Bay Area, positions us to root ourselves in China while maintaining a global perspective. It will serve as a strategic hub for attracting world-class talent.”
Dr. Shi Shuangmei stated, “The market for early cancer screening and diagnosis is growing rapidly internationally, but given its market size and population base, China holds even greater potential. New Horizon Health demonstrates resolute R&D investment and clear product moats; the company has a clear strategy and strong execution capability. My entire family has relocated from Silicon Valley to Hong Kong, and we are eagerly looking forward to embarking on this entrepreneurial journey together to change the trajectory of lives!”
Hong Kong Science Park, located in the New Territories adjacent to the Pak Shek Kok Promenade, is one of the flagship innovation and technology platforms established by the Hong Kong Special Administrative Region Government. Over the past two decades since its inception, the park has primarily incubated companies in the technology and biotechnology sectors. It currently hosts more than 1,100 tech enterprises and employs 11,000 R&D personnel. In the last five years, companies within the park have collectively raised over HK$80.2 billion in funding.
On May 23, 2022, New Horizon Health and Prenetics Group Limited (NASDAQ: PRE, hereinafter referred to as “Prenetics”) announced a strategic partnership to promote Colotect, the first product in China to receive approval for early cancer screening.®(ColoClear by Circle) Listed in Hong Kong and gradually expanding into Southeast Asia. Under the strategic cooperation agreement, New Horizon Health and Prenetics will fully integrate their high-quality resources in market and channel expansion as well as product and service operations, jointly promoting the launch and market coverage of Colosure in Hong Kong, Macau, and Taiwan, China, while simultaneously exploring market opportunities in Southeast Asian countries or regions. During the term of cooperation, Colosure is the exclusive colorectal cancer early screening product partnered with Prenetics.
June 8 Chang Weiqing®Successfully launched in Hong Kong, with an official local price of HKD 3,000 per test. Alex Fong, a renowned Hong Kong entertainer and former Olympic swimmer, serves as the brand ambassador for ColoClear by Circle in the Hong Kong region.
About New Horizon Health
Founded in Hangzhou, Zhejiang Province in 2015, New Horizon Health is China’s first biotech high-tech company specializing in at-home early screening for high-incidence cancers. It also pioneered the industry by becoming the first to successfully list on the Hong Kong Stock Exchange, earning the title of “China’s No. 1 Cancer Early Screening Stock,” with stock code 6606.HK.
With the mission of “changing the trajectory of life,” New Horizon Health adheres to a product philosophy grounded in scientific evidence, clinical validation, user demand, and market potential, making significant investments in the independent research and development of multi-omics cancer screening technologies and product innovation. Targeting colorectal cancer and gastric cancer—the two most prevalent gastrointestinal cancers in China—the company has successfully launched and commercialized three industry-first flagship products: Colotect®- Pupu Tube®and Youyou Tube®。
Changweiqing® is currently the only cancer screening product in China approved by the National Medical Products Administration, suitable for individuals aged 40–74 at high risk for colorectal cancer. Youyouguan® is the first Helicobacter pylori consumer self-test product in China approved by the National Medical Products Administration. Pupuguan®It is China’s first approved home-use fecal immunochemical test (FIT) kit. In addition, the company has three products in development for liver cancer (Gan Zheng Qing™), cervical cancer (Gong Zheng Qing™), and nasopharyngeal cancer screening that have entered or are about to enter registrational clinical trials, as well as multiple other pipeline products for cancer screening. The company holds global intellectual property rights for all its marketed and pipeline products.
Building on its foundation in the clinical market, New Horizon Health has innovatively pioneered diversified business models in the cancer early screening industry, establishing extensive and deep strategic partnerships with cross-industry leading brands, including renowned chain health examination institutions, insurance companies, chain pharmacies, and various internet healthcare platforms. The company’s flagship products have been adopted by nearly 1,000 hospitals across China, creating a closed-loop service for early screening and diagnosis that integrates outpatient care with in-hospital health examinations. With a foothold in the domestic market, New Horizon Health initiated its overseas expansion in 2022; in June, the company partnered with Prenetics, a NASDAQ-listed company in the United States, to launch Colotect in Hong Kong, China.®, and plans to gradually expand its coverage to Macao, China and Taiwan, China in the future, thereby entering the Southeast Asian market. During the same period, the company initiated the construction of an international R&D center located at the Hong Kong Science Park, focusing on multi-omics research and development as well as product development, including next-generation sequencing (NGS) technologies.
New Horizon Health, a publicly listed company, participated in the establishment of the NHH Venture Fund in August 2021, with a focus on investing in breakthrough innovative molecular diagnostic technologies for major human diseases. To date, the company has reached investment or strategic cooperation agreements with five globally leading biotech companies specializing in cancer screening or detection from the United States, Germany, Switzerland, and Singapore.
New Horizon Health operates a 100,000-class cleanroom production facility in Hangzhou that complies with ISO 13485 and ISO 9001 international certification standards. The company has also established third-party medical testing laboratories in Beijing, Hangzhou, and Guangzhou. All three laboratories have obtained quality system certifications aligned with relevant international standards, as well as accreditation from the local Municipal Health Commissions, including the issuance of Medical Institution Practice Licenses.